If you want the real retatrutide before and after clinical data — not a sponsored Instagram transformation, not a forum post from someone who bought grey-market vials — the numbers from Lilly’s Phase 3 program are the only numbers that count. And they are extraordinary. But they are also complicated. Three pivotal trials reported in seven months: TRIUMPH-4 in December 2025, TRANSCEND-T2D-1 in March 2026, and TRIUMPH-1 in May 2026. Together they cover obesity, type 2 diabetes, and knee osteoarthritis across more than 3,300 patients. The best-case number — 30.3% body weight loss sustained for two years — is the highest ever produced by any drug in a controlled trial. But that number only tells part of the story. The full retatrutide before and after clinical data reveals a drug that rewrites expectations and also introduces trade-offs patients need to weigh carefully.
The Retatrutide Before and After Clinical Data You Need to See
The TRIUMPH-1 trial, reported on May 21, 2026, enrolled 2,339 adults with obesity (BMI ≥30, or ≥27 with a weight-related comorbidity) and no diabetes. At 80 weeks on the 12 mg dose, participants lost an average of 28.3% of their body weight — roughly 70 pounds from a starting weight of 250 lbs. Every dose hit its primary endpoint. Even the 4 mg arm — the lowest tested — produced 19.0% weight loss, which already beats semaglutide 2.4 mg’s 14.9% in STEP 1. The 9 mg arm hit 25.9%. These are not statistical artefacts. They are real, measured, peer-review-pending results from a registration-quality trial.
But the headline that deserves more attention is in the 104-week extension. For the 532 participants with a baseline BMI of 35 or higher who stayed on treatment, the 12 mg group averaged 30.3% weight loss at two years — 85 pounds. And crucially, no weight-loss plateau was observed. Participants were still losing weight at week 104. Kenneth Custer, Ph.D., executive vice president and president of Lilly Cardiometabolic Health, called this “the powerful effect of retatrutide, a first-in-class triple agonist, on body weight, pain and physical function.” No GLP-1-class drug has ever produced a mean weight loss above 30% in a pivotal trial. Retatrutide just did.
What the Before and After Looks Like in Knee Osteoarthritis
TRIUMPH-4 was the first Phase 3 trial to report, and it studied a different question: can weight loss from retatrutide meaningfully improve pain and function in people with obesity and knee osteoarthritis? The answer is yes, and the numbers are hard to dismiss. At 68 weeks, the 12 mg group lost 28.7% of body weight (71.2 lbs) and reduced WOMAC pain scores by 75.8% — an average drop of 4.5 points on a 0–20 scale. Physical function scores improved 73.7%. And 12.0% of 12 mg patients reported being completely free of knee pain by the end of the trial — versus 4.2% on placebo.
The weird detail: In a post-hoc analysis, 14.1% of the 9 mg group — a higher percentage than the 12 mg group — reported zero knee pain. That inversion suggests the pain-relief mechanism is not purely a function of weight loss. Glucagon receptor activation may have direct anti-inflammatory or analgesic effects independent of body mass reduction. The finding needs prospective replication, but it hints at a mechanism no other obesity drug has shown.
What the Diabetes Data Changes
TRANSCEND-T2D-1, reported March 19, 2026, enrolled 537 adults with type 2 diabetes (mean duration 2.5 years, baseline A1C 7.9%) who were not adequately controlled on diet and exercise alone. Retatrutide 12 mg produced a 2.0% A1C reduction, taking the average participant from a starting A1C of 7.9% down to approximately 6.0% — within the non-diabetic range. Weight loss at 12 mg hit 16.8% (36.6 lbs), and crucially, weight loss was still trending downward at week 40 with no plateau.
This matters because every other GLP-1 drug — semaglutide, tirzepatide, liraglutide — reaches a weight-loss plateau somewhere between weeks 30 and 40 in diabetes populations. Retatrutide does not appear to hit that ceiling. The likely reason is the glucagon receptor mechanism, which increases energy expenditure and fat oxidation independently of appetite suppression. For patients with type 2 diabetes who have historically been told to expect modest weight loss from diabetes medications, this is a fundamentally different proposition.
The 9 mg dose produced a slightly larger A1C drop (−2.0%) than 12 mg (−1.9%). That statistical oddity — the middle dose outperforming the top dose on glycemic control — may reflect a ceiling effect at these A1C levels, but it suggests that most of the glycemic benefit is captured at 9 mg, with the additional glucagon drive at 12 mg serving weight loss more than glucose lowering.
The Safety Trade-Off No One Wants to Talk About
Here is where the retatrutide before and after clinical data demands honesty. The side effect profile is not a footnote.
Gastrointestinal effects are the known variable. In TRIUMPH-4, 43.2% of 12 mg patients reported nausea, 33.1% diarrhea, 25.0% constipation, and 20.9% vomiting. In TRIUMPH-1, the GI rates were similar — nausea 42.4%, diarrhea 32.0%, constipation 26.1%, vomiting 25.3%. These are consistent with the GLP-1 class but at the upper end of the range. Discontinuation due to adverse events at 12 mg was 11.3% in TRIUMPH-1 and 18.2% in TRIUMPH-4 — significantly higher than placebo (4.9% and 4.0%, respectively). For patients with baseline BMI ≥35 in TRIUMPH-4, the AE-related discontinuation rate dropped to 12.1%, suggesting tolerability may be better in patients with more severe obesity.
The dysesthesia signal is the new variable. In TRIUMPH-4, 20.9% of 12 mg patients reported skin tingling, burning, or abnormal sensation, versus 0.7% on placebo. These events were generally mild and most resolved during treatment, but they are not something patients on semaglutide or tirzepatide typically encounter. In TRIUMPH-1, the rate was lower — 12.5% at 12 mg — suggesting the signal is real but population-dependent. TRANSCEND-T2D-1 reported only 4.4% at 12 mg. The mechanism is not fully understood, but the leading hypothesis involves glucagon receptor activation in peripheral nerve tissue. It is dose-dependent, it is almost always reversible, and it rarely causes discontinuation, but patients should be informed before starting treatment, not after.
Who Wins and Who Gets Left Behind
The responder analysis from TRIUMPH-1 tells you who benefits most. In the 12 mg arm:
- 62.5% lost 25% or more of their body weight
- 45.3% lost 30% or more
- 27.2% lost 35% or more — bariatric surgery territory
- 65.3% dropped below a BMI of 30, exiting the obese category entirely
- Among those starting with a BMI of 40 or higher, 37.5% still reached a BMI under 30
Those are exceptional numbers. But they also mean that roughly 35% of patients in the 12 mg arm did not lose 25% of their body weight, and approximately 10% lost less than 10%. The mean pulls the story in one direction; the distribution is more complicated. The drug is not a uniform solution. Individual response variability remains wide, and there is no way to predict who will be a high responder before they start.
And the trade-off that deserves more airtime: weight regain is almost certain when treatment stops. TRIUMPH trials do not include a randomized off-treatment phase, so the question is unanswered for retatrudide specifically. But the SURE trial showed that semaglutide users regained approximately two-thirds of lost weight within one year of discontinuation. There is no biological reason to expect retatrudide to be different. The drug suppresses appetite and increases energy expenditure; when it stops, both return to baseline. Anyone starting retatrudide should plan for long-term — potentially lifelong — treatment. That is a significant commitment with financial, practical, and tolerability implications.
The Timeline Question
Lilly has guided for an NDA submission in late 2026 to early 2027, contingent on positive readouts from the remaining TRIUMPH trials — particularly TRIUMPH-2 (obesity + type 2 diabetes, expected Q2–Q3 2026) and TRIUMPH-3 (obesity + established cardiovascular disease, expected later in 2026). A standard 10- to 12-month FDA review puts earliest approval in late 2027 to early 2028. Priority Review could compress that by about 4 months, but Lilly has not confirmed it will request it. The dedicated cardiovascular outcomes trial (TRIUMPH-Outcomes, ~10,000 patients) is a 3- to 4-year study, meaning cardiovascular labeling will not accompany the initial approval. Patients who need CV risk data before committing to a new drug will need to wait.
Take a Side: What the Data Actually Demands
Here is the position the evidence forces: retatrutide is the most effective weight-loss drug ever tested in a Phase 3 trial. The 28.3% mean in TRIUMPH-1, the 30.3% in the 104-week extension, the 45.3% of patients who lost 30% or more of their body weight — none of these have been matched by any approved or investigational agent. The 75.8% pain reduction in TRIUMPH-4 hints at benefits that go beyond weight loss alone. For patients with severe obesity and OA who are considering knee replacement, retatrutide may offer something no other medication has: sufficient weight loss and pain reduction to defer or avoid surgery entirely.
But the dysesthesia signal is real and needs to be monitored. The 11–18% discontinuation rate at the top dose is meaningful. And the certainty of weight regain on discontinuation means this is a long-term commitment, not a metabolic reset. The trial data does not tell you whether you will be the 62.5% responder or part of the tail that loses single-digit weight. It tells you what the drug can do, not what it will do for you.
That is the honest read of the retatrutide before and after clinical data. It is the best pharmacological option available — with trade-offs that demand informed consent, realistic expectations, and a plan for the long term.
Leave a Reply